Day 1: Tuesday September 16Tuesday, 16 September 2025

Reviewing the unprecedented growth of the obesity therapeutics market, as obesity is recognized a complex chronic disease. Highlighting current approaches, strategies and partnerships driving innovation in the field.

• What modalities are empowering the growth of the obesity therapeutics market?

• What new targets is the industry looking at beyond GLP-1R?

• What next steps must be taken to accelerate patient adherence and reduce side effects of weight-loss drugs?

• How can appetite suppressing and energy expenditure drugs be synergized?

• Highlighting the most impactful collaborations from the past year

• Which approaches and targets are pharma looking at most?

• How are pharma evaluating potential partnerships with early-stage biotech and academia?

• Exploring updates on oral small molecule GLP-1R candidate, RGT-075, as it progresses through Phase 2b clinical trials
• Insight into the rCARDTM propriety platform to enable accelerated drug discovery within obesity therapeutics

• DA-1726 is being developed by MetaVia Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist with a 3:1 GLP1R to GCGR ratio.

• OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.

• In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction.

• Developing a GLP-1 agonist-ActR2A/B monoclonal antibody conjugate for adipose specific weight loss alongside maintained skeletal muscle mass

• Exploring pre-clinical updates, as well as insight into further weight-loss drug conjugates beyond GLP-1 agonists

• Utilising a unique triple monoamine reuptake inhibitor, tesofensine, to increase brain levels of dopamine, serotonin and noradrenaline for regulation of food seeking behaviour

• Highlighting Phase 3 clinical updates

• Biology and genetics of MC4R-deficiency
• Discovery and pharmacology of small molecules stabilizers of misfolded MC4R

• GLP-1 agonists have transformed obesity treatment, but opportunities remain to improve weight loss and preserve lean mass through complementary mechanisms
• BioAge is developing compounds targeting two novel mechanisms: BGE-102, a brain-penetrant NLRP3 inhibitor targeting appetite driven by neuroinflammatory signaling, and APJ agonists that mimic exercise to increase energy expenditure while improving body composition
• Both mechanisms show synergistic effects with incretins in preclinical models, representing a new paradigm of rationally designed combinations to optimize weight loss quality and quantity

• Showcasing latest efficacy data for small-molecule uncoupling enhancer in animal models of obesity: from muscle-preserving weight loss monotherapy to robust weight maintenance post GLP-1 discontinuation

• Discovery and characterization of an adipose tissue-enriched small molecule mitochondrial uncoupler that enhances energy expenditure
• Demonstrating preclinical efficacy and safety by adipose-enriched mitochondrial uncoupling